Analysis of the cost of pharmacotherapy of ischemic stroke in hospital in 2009-2011
Abstract
Pharmacoeconomic analysis includes the assessment of direct cost structure in pharmacotherapy of cerebral infarction for the period of 2009-2011 in healthcare institutions in Saratov (762 patients) based on ABC analysis and frequency analysis. The results of the mentioned analysis showed the presence of drugs without proven efficacy and a very high associated cost component (75.67%) of purchasing budget in drug group «A». It was revealed, that the drugs of scientifically substantiated efficacy and safety are not used sufficiently in treatment of cerebral infarction. On the other hand the drugs without proven efficacy are widely used, which leads to an increase in financial losses of the state and population. The results of clinical and economic analysis showed the need for changing the cost structure for drug therapy of the mentioned disease in hospitals.
About the Authors
N. V. Mikheeva
State Budgetary Educational Institution HVE «Saratov State Medical University named after V.I. Razumovsky» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. V. Reshetko
State Budgetary Educational Institution HVE «Saratov State Medical University named after V.I. Razumovsky» of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
S. I. Kurnosov
State Healthcare Institution «Regional Clinical Hospital»
Russian Federation
Russian Federation
References
1. Hojs R. Renal Dysfunction and Ischemic Stroke. Scientific Journal of the Faculty of Medicine in Niš. 2013; 30(4): 185–191.
2. Belousov DY. Pharmacoeconomics: why, where and how to conduct pharmacoeconomic studies? Farmakoekonomika 2011; (1): 13–15 (in Russian).
3. Ostrovskaya VO. Evaluation of clinical practice: the treatment of patients with acute stroke. Lekarstvenny vestnik 2012; 6(46): 31–38 (in Russian).
4. Fonyakin AV. Topical areas of secondary prevention of ischemic stroke. Nervnye bolezni 2012; (2): 2–7 (in Russian).
5. Shandalin VA. Secondary prevention of ischemic stroke: from recommendations – to the clinical practice. Nevrologiya, neyropsihiatriya, psihosomatika 2012; (2): 35–41.
6. Laslett LJ. The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues. A Report From the American College of Cardiology. J Am Coll Cardial. 2012; 60(25): 1–49.
7. Alfimova GYu. Register stroke in the Smolensk region. Bulleten sibirskoy meditsiny 2008; (5): 19–23 (in Russian).
8. Martynchik SA. Medico-economic evaluation and justification of improving organizational forms of inpatient care for stroke. Available from: http://vestnik.mednet.ru/content/view/473/30/lang.ru/ (in Russian).
9. Simerzin VV. Rational Pharmacotherapy in Cardiology. Vestnik Samarskogo gosudarstvennogo universiteta 2008; 2(61): 303–11.
10. Wiffen P. Adverse drug reactions in hospital patients: a systematic review of the prospective and retrospective studies. Bandolier Extra 2002; June: 1–16.
11. Sapozhnikova IE. Treatment of cardiovascular diseases in patients with Type 2 diabetes in the clinical practice. Ratsionalnaya farmakoterapiya v kardiologii 2009; (3): 8–13 (in Russian).
12. Kotelnikov GP. Evidence-based medicine. Evidence-based medical practice: Monograph. Samara: Samara State Medical University; 2000 (in Russian).
13. World Health Organisation: The World Medicines Situation 2011. Rational use of medicines. Geneva: WHO; 2011.
14. Starodubov VI. Conceptual issues of health care and pharmaceutical sector of the Russian Federation. St. Petersburg: St. Petersburg State Medical University; 1999. (in Russian).
15. Belousov YuB. Fundamentals of clinical pharmacology and rational pharmacotherapy. Volume I. Guidelines for practitioners. Moscow: Bionika; 2002 (in Russian).
16. Petrov VI. Clinical pharmacology and pharmacotherapy in real medical practice: a master class: the textbook. Moscow: GEOTAR-Media; 2011 (in Russian).
17. Belousov DYu. Pharmacoeconomics: why, where and how to conduct pharmacoeconomic studies? Farmakoekonomika 2011; (1): 13–15 (in Russian).
18. Yagudina RI. Analysis Methodology «cost-effectiveness» in conducting pharmacoeconomic studies. Farmakoekonomika 2012; 5(4): 3–8 (in Russian).
19. Gusev EI. Neurology. National guide. Moscow: GEOTAR-Media; 2009 (in Russian).
20. Saver JL. Citicoline: update on a promising and widely available agent for neuroprotection and neurorepair. Rev Neurol Dis. 2008; 5(4): 167–77.
21. Bolland K. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharm Stat. 2009; 8(2): 136–49.
22. Dávalos A. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet 2012; 380(9839): 349–57.
23. Álvarez-Sabín J. The Role of Citicoline in Neuroprotection and Neurorepair in Ischemic Stroke. Brain Sci. 2013; 3(3): 1395–414.
24. Overgaard К. The Effects of Citicoline on Acute Ischemic Stroke: A Review. The Journal of Stroke & Cerebrovascular Diseases 2014; 23(7): 1764–69.
25. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines formanagement of ischaemic strokea nd transient ischaemic attack. Cerebrovasc Dis. 2008; 25: 457–507.
26. Jauch EC. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 31(4): 870–947.
27. Kamphuisen PW. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost. 2005; (3): 1187–94.
28. Diener HC. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: Results of the protect trial. Stroke 2006; 37: 139–44.
29. Sherman DG. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (prevail study): An open-label randomised comparison. Lancet 2007; 369: 1347–55.
30. Bardutzky J. Antiedema Therapyin Ischemic Stroke. Stroke 2007; 38: 3084–94.
31. Bath PM. Theophylline, aminophylline, caffeine and analogues for acute ischaemic stroke (Review). The Cochrane Collaboration 2009; (1): 1–14.
32. Norris JW. High dose steroid treatment in cerebral infarction. Br Med J (Clin Res Ed) 1986; 292(6512): 21–23.
33. Qizilbash N. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12076379
34. Sandercock PA. Corticosteroids for acute ischaemic stroke. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21901674
35. Adams HP. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline From the American Heart Association. American Stroke Association. Stroke 2007; 38: 1655–711.
36. Ziganshina LE. Cerebrolysin in the treatment of acute ischemic stroke. Vestnik RAMN 2013; (1): 21–29 (in Russian).
37. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chin Med J (Engl) 1995; 108(9): 710–17.
38. PROGRESS Collaborative Group. Randomised trial of perindopril-based blood- pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
39. Castillo J. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain in jury and poor stroke out come. Stroke 2004; 35: 520–26.
40. Eveson DJ. Lisinopril for the treatment of hypertension within the first 24 hours of acute ischemic stroke and follow-up. Am J Hypertens 2007; 20(3): 270–7.
41. Amarenco P. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006; 355: 549–59.
42. Furie KL. Heart Protection Study Collaborative Group: Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7–22.
Review
For citations:
Mikheeva N.V., Reshetko O.V., Kurnosov S.I. Analysis of the cost of pharmacotherapy of ischemic stroke in hospital in 2009-2011. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(2):59-64. (In Russ.)
Views:
512
Email this article 